Winslow Evans & Crocker Inc. maintained its stake in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,050 shares of the medical technology company’s stock at the end of the second quarter. Winslow Evans & Crocker Inc.’s holdings in Stryker Corporation were worth $146,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of SYK. Baystate Wealth Management LLC raised its stake in shares of Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock worth $139,000 after buying an additional 22 shares during the period. James Investment Research Inc. acquired a new stake in shares of Stryker Corporation during the second quarter worth approximately $155,000. Guardian Life Insurance Co. of America raised its stake in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after buying an additional 9 shares during the period. Assetmark Inc. raised its stake in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after buying an additional 4 shares during the period. Finally, Mosaic Family Wealth LLC raised its stake in shares of Stryker Corporation by 3.5% in the first quarter. Mosaic Family Wealth LLC now owns 1,300 shares of the medical technology company’s stock worth $171,000 after buying an additional 44 shares during the period. Institutional investors and hedge funds own 74.16% of the company’s stock.

Stryker Corporation (NYSE SYK) traded down 0.26% during trading on Wednesday, reaching $139.05. The company had a trading volume of 234,658 shares. The firm’s 50-day moving average price is $144.80 and its 200 day moving average price is $137.03. The firm has a market capitalization of $52.01 billion, a P/E ratio of 31.04 and a beta of 0.80. Stryker Corporation has a one year low of $106.48 and a one year high of $148.84.

Stryker Corporation (NYSE:SYK) last released its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. During the same quarter in the prior year, the firm earned $1.39 EPS. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. Equities analysts forecast that Stryker Corporation will post $6.47 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be given a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.22%. Stryker Corporation’s dividend payout ratio (DPR) is presently 37.95%.

COPYRIGHT VIOLATION NOTICE: “Winslow Evans & Crocker Inc. Has $146,000 Position in Stryker Corporation (SYK)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/winslow-evans-crocker-inc-has-146000-position-in-stryker-corporation-syk/1532274.html.

A number of brokerages recently commented on SYK. BidaskClub upgraded Stryker Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Canaccord Genuity reissued a “buy” rating and issued a $155.00 target price (down from $158.00) on shares of Stryker Corporation in a research report on Thursday, August 24th. Zacks Investment Research downgraded Stryker Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Argus reissued a “buy” rating and issued a $160.00 target price on shares of Stryker Corporation in a research report on Tuesday. Finally, Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Stryker Corporation in a research report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $145.73.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the sale, the insider now owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the sale, the insider now directly owns 8,983 shares of the company’s stock, valued at approximately $1,313,853.58. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,810 shares of company stock valued at $4,754,958. Insiders own 7.40% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.